Lasa Supergenerics Analyst Review May 2026

This Lasa Supergenerics analyst review for May 2026 covers the key data investors need for LASA at its current price of Rs 7.6. Lasa Supergenerics (NSE: LASA) is a veterinary API and pharmaceutical company with a market capitalisation of approximately Rs 180 crore. The analyst consensus target of Rs 12 implies meaningful upside, and this Lasa Supergenerics analyst review examines technical levels, business performance, valuation, and key risks for LASA through FY27.

Click Here – Get Free Investment Predictions

Lasa Supergenerics Company Snapshot May 2026

Lasa Supergenerics manufactures veterinary APIs, human pharma intermediates, and specialty molecules. The company has been working through profitability challenges and is focused on operational recovery. The table below summarises the key data referenced in this Lasa Supergenerics analyst review.

Parameter	Value
NSE Ticker	LASA
Sector	Pharmaceuticals – Veterinary APIs
CMP (May 2026)	Rs 7.6
52 Week High	Rs 19.65
52 Week Low	Rs 5.65
Market Cap	Rs 180 Crore
Trailing P/E	NAx
Analyst Consensus Target	Rs 12
Bull Case Target	Rs 16
Bear Case Target	Rs 6

Analyst Insight in This Lasa Supergenerics Analyst Review

Senior Research Analyst Ankit Jaiswal flags Lasa Supergenerics as a stock to watch in May 2026. At Rs 7.6, Ankit Jaiswal identifies key support in the Rs 5.76 to Rs 7.22 band and resistance near Rs 8.06. He suggests watching Lasa Supergenerics for a potential move toward Rs 12, subject to Pharmaceuticals – Veterinary APIs sector momentum. Ankit Jaiswal’s view is one input in this Lasa Supergenerics analyst review and does not constitute a trade recommendation.

Technical Analysis in This Lasa Supergenerics Analyst Review

At Rs 7.6, LASA is trading within its 52-week band of Rs 5.65 to Rs 19.65. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 5.76 to Rs 7.22 band while resistance is seen in the Rs 8.06 to Rs 9.80 zone. A sustained move above Rs 8.06 could open the path toward the analyst consensus target of Rs 12 as identified in this Lasa Supergenerics analyst review.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

• Support Zone: Rs 5.76 to Rs 7.22 – investors tracking this Lasa Supergenerics analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for LASA.
• Resistance Zone: Rs 8.06 to Rs 9.80 – a sustained close above Rs 8.06 would be a positive breakout signal worth flagging in this Lasa Supergenerics analyst review.
• Medium-Term Target: The analyst consensus of Rs 12 represents the base-case upside scenario in this Lasa Supergenerics analyst review.

Business Segment Analysis

Veterinary API Manufacturing

This is the primary revenue and margin driver for Lasa Supergenerics, directly supporting the earnings trajectory toward the consensus target of Rs 12.

Human Pharmaceutical Intermediates

This segment adds scale and diversification to Lasa Supergenerics’s business model and is a meaningful EPS contributor through FY27 and FY28.

Contract Research and Custom Synthesis

This represents the medium-term growth frontier for Lasa Supergenerics and a key re-rating catalyst for the stock over the next 12 to 24 months.

Valuation in This Lasa Supergenerics Analyst Review

At Rs 7.6, Lasa Supergenerics trades at a trailing P/E of NAx. This Lasa Supergenerics analyst review presents three scenarios: a bull case of Rs 16 on strong earnings delivery, a base case of Rs 12 at analyst consensus, and a bear case of Rs 6 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Lasa Supergenerics analyst review.

Scenario	Target Price	Key Condition
Bull Case	Rs 16	Strong earnings delivery and sector re-rating
Base Case (Consensus)	Rs 12	Moderate growth, analyst consensus estimate
Bear Case	Rs 6	Earnings miss or macro headwinds

Trade Outlook for Lasa Supergenerics

Based on the technical and fundamental analysis in this Lasa Supergenerics analyst review, investors might watch LASA near the support zone of Rs 5.76 to Rs 7.22 for potential opportunities. A flag above Rs 8.06 could suggest improving momentum toward Rs 12. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Lasa Supergenerics in FY27

A well-rounded Lasa Supergenerics analyst review must assess downside risks. Key risks for Lasa Supergenerics include a macro slowdown affecting Pharmaceuticals – Veterinary APIs sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in LASA.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Lasa Supergenerics Analyst Review Verdict for 2026

This Lasa Supergenerics analyst review concludes that at Rs 7.6, LASA offers a defined risk-reward with a consensus target of Rs 12. The 52-week range of Rs 5.65 to Rs 19.65 provides context on the current entry point. Use this Lasa Supergenerics analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on LASA.

Frequently Asked Questions: Lasa Supergenerics Analyst Review 2026

What is the analyst target for Lasa Supergenerics in 2026?

The analyst consensus target is Rs 12, with a bull case of Rs 16 and a bear case of Rs 6. This Lasa Supergenerics analyst review recommends monitoring Q1 FY27 earnings for confirmation.

Is Lasa Supergenerics a good investment at Rs 7.6?

At Rs 7.6 with a P/E of NAx and a consensus target of Rs 12, this Lasa Supergenerics analyst review is constructive for medium to long-term investors in the Pharmaceuticals – Veterinary APIs sector. Always consult a SEBI-registered advisor before investing.

What is Lasa Supergenerics’s 52-week high and low?

The 52-week high is Rs 19.65 and the 52-week low is Rs 5.65. At Rs 7.6, LASA is positioned within this range as noted in this Lasa Supergenerics analyst review.

What are the key risks for Lasa Supergenerics?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals – Veterinary APIs sector as assessed in this Lasa Supergenerics analyst review.

Where can I track live data for Lasa Supergenerics?

Track Lasa Supergenerics’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Lasa Supergenerics analyst review.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.